Faculty

Institution

Unit

Venue

Daniel E. Frigo

Professor Associate Professor Adjunct

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Cancer Medicine

Division Of Diagnostic Imaging

Department Of Cancer Systems Imaging

The University of Texas MD Anderson Cancer Center

Daniel E. Frigo is currently serving as a Cancer Medicine Professor Associate Professor Adjunct at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Daniel E. Frigo

The University of Texas MD Anderson Cancer Center

Professor Associate Professor Adjunct

You can click a keyword to filter the displayed items

prostate cancer urology tumor biology cancer biology cancer research oncology pharmacology cell biology medicinal research cancer cells molecular cancer prostatic disease oncogenes cell signaling molecular biology endocrinology cancer care carcinogenesis signal transduction cancer discovery enzyme inhibition cell metabolism signaling pathways molecular physiology cell regulation androgen receptor molecular metabolism endocrine oncology endocrine-related cancers cancer genetics redox biology molecular cell biology endocrine research cancer treatment autophagy vascular biology in vivo systems tumor targeting metabolic regulation cancer growth tumor suppressors receptor (biochemistry) castration-resistant prostate cancer surgical oncology comparative endocrinology pathway analysis benign prostatic hyperplasia insulin signaling lipid synthesis prostate cancer cells cellular physiology mitochondrial function cell physiology cellular biology andrology steroid metabolism endocrine mechanisms hormonal receptor anti-cancer agents steroid hormones glutamine transporters breast oncology cell interactions oogenesis nano-drug delivery oncogenic properties triple-negative breast cancer androgen receptor-mtor-mediated mechanism pentose phosphate pathway chitosan nanoparticle-mediated delivery tumor growth mir-200a inhibits migration direct repression select organochlorines hexosamine biosynthetic pathway differential regulation

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 4740: Exploiting Ketone Body Metabolism as a Therapeutic Vulnerability in Prostate Cancer. Cancer Research (2026)

pharmacologymetabolic remodelingmolecular cancerabstract 4740urologytherapeutic targetsprostatic diseasemolecular metabolismoncogenescancer cellscancer biologyprostate cancerketone body metabolismcell metabolism

Adiposity and Response to Adt ± Ar Pathway Inhibitors (Arpi) in Men With Metastatic Hormone-Sensitive Prostate Cancer (Mhspc).. Journal of Clinical Oncology (2026)

obesity medicinepharmacologycancer caremetabolic disordersmetabolic syndromeurologyobesitygenitourinary cancersprostatic diseaseoncologyprostate cancerhealth sciences

Cardiometabolic Health’s Influence on Outcomes in Men With Localized High-Risk Prostate Cancer (Hrpca) Treated With Pre-Operative Adt ± Ar Pathway Inhibition (Arpi).. Journal of Clinical Oncology (2026)

medicinecancer carecardiometabolic health ’cardiovascular researchurologyprostatic diseasegenitourinary cancersoncologyprostate cancercardiovascular disease

Influence of Body Composition on the Efficacy of Chemotherapy in Men With Metastatic Aggressive Variant Prostate Cancer (Avpc).. Journal of Clinical Oncology (2026)

metastasiscancer carecancer managementbody compositionurologyprostatic diseasegenitourinary cancersoncologyjama oncologyprostate cancerhealth sciences

Lipids Grease the Chain of Cancer Progression. Trends in cancer (2026)

carcinogenesislipid sciencecancer researchlipidscancer cellscancer progressioncell metabolismtumor biologylipid analysisbiochemistrycell biology

Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study. The Journal of Urology (2026)

grade group progressioncancer careradiation oncologylow testosterone levelsurologyprostatic diseasegenitourinary cancersoncologycancer screeningactive surveillancejama oncologyprostate cancer

Abstract 3123: Fracturing the Tumor-Bone Alliance in Metastatic Prostate Cancer With Ra-223. Cancer Research (2025)

Pablo SanchisAgustina SabaterJuan BizzottoGaston PascualNicolas AnselminoJiabin DongJun YangGaniraju ManyamBradley BroomZhongcheng ShiShixia HuangRocio SeniukEleonora DondossolaTeocharis PanaretakisJohn AraujoPeter ShepherdPatricia TroncosoNora NavoneChristopher J. LogothetisDaniel E. FrigoElba VazquezPaul CornGeraldine GueronEstefania Labanca

tumor-bone alliancecancer researchcancer biologyprostate cancermetastatic prostate cancer

Abstract 6367: Chd1 Loss Hijacks Srebp2-Mediated Cholesterol Biosynthesis to Fuel Spop-Deficient Prostate Cancer and Confers Resistance to Castration. Cancer Research (2025)

clinical lipidologychd1 losssrebp2-mediated cholesterol biosynthesislipoprotein metabolismmetabolic remodelingspop-deficient prostate cancerlipidslipid synthesismolecular metabolismmolecular biologymetabolic pathwayscell metabolismprostate cancerbiochemistrycell biology

Adaptation of the Predimed Intervention for Medically Underserved Prostate Cancer Patients Through Intervention Mapping. medRxiv (2025)

multimodality therapycancer careimplementation researchintervention mappingradiation oncologysurgical oncologyurologyprostatic diseaseoncologyprostate cancerpredimed intervention

Chd1 Loss Reprograms Srebp2-Driven Cholesterol Synthesis to Fuel Androgen-Responsive Growth and Castration Resistance in Spop-Mutated Prostate Tumors. Nature Cancer (2025)

endocrine-related cancerschd1 losscancer biologycastration resistancelipidsmolecular cancerurologytumor suppressorslipid synthesisprostatic diseasesrebp2-driven cholesterol synthesisprostate canceroncogenescancer cellscell metabolismtumor biologycell biology

1
2
3
4
5
10
10 / page

Daniel E. Frigo

Professor Associate Professor Adjunct

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Cancer Medicine

Division Of Diagnostic Imaging

Department Of Cancer Systems Imaging

The University of Texas MD Anderson Cancer Center

Daniel E. Frigo is currently serving as a Cancer Medicine Professor Associate Professor Adjunct at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Daniel E. Frigo

The University of Texas MD Anderson Cancer Center

Professor Associate Professor Adjunct

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 4740: Exploiting Ketone Body Metabolism as a Therapeutic Vulnerability in Prostate Cancer. Cancer Research (2026)

Adiposity and Response to Adt ± Ar Pathway Inhibitors (Arpi) in Men With Metastatic Hormone-Sensitive Prostate Cancer (Mhspc).. Journal of Clinical Oncology (2026)

obesity medicinepharmacologycancer caremetabolic disordersmetabolic syndromeurologyobesitygenitourinary cancersprostatic diseaseoncologyprostate cancerhealth sciences

medicinecancer carecardiometabolic health ’cardiovascular researchurologyprostatic diseasegenitourinary cancersoncologyprostate cancercardiovascular disease

Influence of Body Composition on the Efficacy of Chemotherapy in Men With Metastatic Aggressive Variant Prostate Cancer (Avpc).. Journal of Clinical Oncology (2026)

metastasiscancer carecancer managementbody compositionurologyprostatic diseasegenitourinary cancersoncologyjama oncologyprostate cancerhealth sciences

Lipids Grease the Chain of Cancer Progression. Trends in cancer (2026)

carcinogenesislipid sciencecancer researchlipidscancer cellscancer progressioncell metabolismtumor biologylipid analysisbiochemistrycell biology

Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study. The Journal of Urology (2026)

grade group progressioncancer careradiation oncologylow testosterone levelsurologyprostatic diseasegenitourinary cancersoncologycancer screeningactive surveillancejama oncologyprostate cancer

Abstract 3123: Fracturing the Tumor-Bone Alliance in Metastatic Prostate Cancer With Ra-223. Cancer Research (2025)

tumor-bone alliancecancer researchcancer biologyprostate cancermetastatic prostate cancer

Abstract 6367: Chd1 Loss Hijacks Srebp2-Mediated Cholesterol Biosynthesis to Fuel Spop-Deficient Prostate Cancer and Confers Resistance to Castration. Cancer Research (2025)

Adaptation of the Predimed Intervention for Medically Underserved Prostate Cancer Patients Through Intervention Mapping. medRxiv (2025)

multimodality therapycancer careimplementation researchintervention mappingradiation oncologysurgical oncologyurologyprostatic diseaseoncologyprostate cancerpredimed intervention

Chd1 Loss Reprograms Srebp2-Driven Cholesterol Synthesis to Fuel Androgen-Responsive Growth and Castration Resistance in Spop-Mutated Prostate Tumors. Nature Cancer (2025)

1
2
3
4
5
10
10 / page